(SXI) Standex International - Overview
Stock: Sensors, Relays, Engraving Tools, Scientific Equipment, Hydraulic Cylinders
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.69% |
| Yield on Cost 5y | 1.97% |
| Yield CAGR 5y | 7.32% |
| Payout Consistency | 95.4% |
| Payout Ratio | 15.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 36.2% |
| Relative Tail Risk | -4.43% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.82 |
| Alpha | 12.82 |
| Character TTM | |
|---|---|
| Beta | 1.200 |
| Beta Downside | 1.104 |
| Drawdowns 3y | |
|---|---|
| Max DD | 38.01% |
| CAGR/Max DD | 0.81 |
Description: SXI Standex International January 14, 2026
Standex International Corp. (NYSE:SXI) is a diversified manufacturer serving commercial and industrial markets worldwide through five segments: Electronics, Engineering Technologies, Scientific, Engraving, and Specialty Solutions. Its product portfolio spans reed relays, custom sensors, transformers, precision molding tools, temperature-controlled biotech equipment, and hydraulic cylinders, marketed under a range of brand names such as Standex-Meder, Agile Magnetics, Spincraft, and Federal.
Key operating metrics (FY 2023) show revenue of roughly $1.4 billion, with the Electronics segment contributing about 55 % of sales and delivering an adjusted EBITDA margin near 8 %. The company’s dividend yield sits around 1.2 % and it has a modest share-repurchase program, reflecting a focus on returning cash to shareholders. Standex’s performance is closely tied to macro drivers like U.S. defense spending (which underpins its aerospace and stealth-aircraft tooling business) and the broader industrial automation trend that fuels demand for custom sensors and electronic assemblies.
For a deeper, data-rich assessment of SXI’s valuation dynamics and peer comparisons, you might explore the analytics platform ValueRay, which aggregates real-time financial metrics and scenario modeling tools.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 53.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.33 > 1.0 |
| NWC/Revenue: 36.83% < 20% (prev 45.53%; Δ -8.69% < -1%) |
| CFO/TA 0.05 > 3% & CFO 80.3m > Net Income 53.9m |
| Net Debt (513.7m) to EBITDA (156.3m): 3.29 < 3 |
| Current Ratio: 2.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (12.1m) vs 12m ago 0.25% < -2% |
| Gross Margin: 39.99% > 18% (prev 0.39%; Δ 3960 % > 0.5%) |
| Asset Turnover: 57.19% > 50% (prev 48.40%; Δ 8.79% > 0%) |
| Interest Coverage Ratio: 3.68 > 6 (EBITDA TTM 156.3m / Interest Expense TTM 34.2m) |
Altman Z'' 5.57
| A: 0.21 (Total Current Assets 490.7m - Total Current Liabilities 170.8m) / Total Assets 1.55b |
| B: 0.73 (Retained Earnings 1.14b / Total Assets 1.55b) |
| C: 0.08 (EBIT TTM 126.0m / Avg Total Assets 1.52b) |
| D: 1.22 (Book Value of Equity 990.1m / Total Liabilities 809.8m) |
| Altman-Z'' Score: 5.57 = AAA |
Beneish M -3.18
| DSRI: 0.70 (Receivables 176.6m/208.8m, Revenue 868.6m/717.7m) |
| GMI: 0.97 (GM 39.99% / 38.91%) |
| AQI: 0.97 (AQ_t 0.55 / AQ_t-1 0.57) |
| SGI: 1.21 (Revenue 868.6m / 717.7m) |
| TATA: -0.02 (NI 53.9m - CFO 80.3m) / TA 1.55b) |
| Beneish M-Score: -3.18 (Cap -4..+1) = AA |
What is the price of SXI shares?
Over the past week, the price has changed by +3.04%, over one month by +6.34%, over three months by +6.84% and over the past year by +30.56%.
Is SXI a buy, sell or hold?
- StrongBuy: 2
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SXI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 271.8 | 6.9% |
| Analysts Target Price | 271.8 | 6.9% |
| ValueRay Target Price | 325 | 27.8% |
SXI Fundamental Data Overview February 09, 2026
P/E Forward = 28.9855
P/S = 3.5472
P/B = 4.4
P/EG = 0.9516
Revenue TTM = 868.6m USD
EBIT TTM = 126.0m USD
EBITDA TTM = 156.3m USD
Long Term Debt = 534.7m USD (from longTermDebt, last quarter)
Short Term Debt = 11.1m USD (from shortTermDebt, last fiscal year)
Debt = 610.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 513.7m USD (from netDebt column, last quarter)
Enterprise Value = 3.59b USD (3.08b + Debt 610.7m - CCE 97.0m)
Interest Coverage Ratio = 3.68 (Ebit TTM 126.0m / Interest Expense TTM 34.2m)
EV/FCF = 69.69x (Enterprise Value 3.59b / FCF TTM 51.6m)
FCF Yield = 1.43% (FCF TTM 51.6m / Enterprise Value 3.59b)
FCF Margin = 5.94% (FCF TTM 51.6m / Revenue TTM 868.6m)
Net Margin = 6.20% (Net Income TTM 53.9m / Revenue TTM 868.6m)
Gross Margin = 39.99% ((Revenue TTM 868.6m - Cost of Revenue TTM 521.3m) / Revenue TTM)
Gross Margin QoQ = 39.67% (prev 41.59%)
Tobins Q-Ratio = 2.31 (Enterprise Value 3.59b / Total Assets 1.55b)
Interest Expense / Debt = 1.30% (Interest Expense 7.91m / Debt 610.7m)
Taxrate = 24.06% (6.54m / 27.2m)
NOPAT = 95.7m (EBIT 126.0m * (1 - 24.06%))
Current Ratio = 2.87 (Total Current Assets 490.7m / Total Current Liabilities 170.8m)
Debt / Equity = 0.87 (Debt 610.7m / totalStockholderEquity, last quarter 700.2m)
Debt / EBITDA = 3.29 (Net Debt 513.7m / EBITDA 156.3m)
Debt / FCF = 9.96 (Net Debt 513.7m / FCF TTM 51.6m)
Total Stockholder Equity = 701.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.55% (Net Income 53.9m / Total Assets 1.55b)
RoE = 7.68% (Net Income TTM 53.9m / Total Stockholder Equity 701.6m)
RoCE = 10.19% (EBIT 126.0m / Capital Employed (Equity 701.6m + L.T.Debt 534.7m))
RoIC = 7.63% (NOPAT 95.7m / Invested Capital 1.25b)
WACC = 8.79% (E(3.08b)/V(3.69b) * Re(10.34%) + D(610.7m)/V(3.69b) * Rd(1.30%) * (1-Tc(0.24)))
Discount Rate = 10.34% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.83%
[DCF Debug] Terminal Value 73.93% ; FCFF base≈52.6m ; Y1≈48.7m ; Y5≈44.1m
Fair Price DCF = 14.04 (EV 683.9m - Net Debt 513.7m = Equity 170.2m / Shares 12.1m; r=8.79% [WACC]; 5y FCF grow -9.42% → 2.90% )
EPS Correlation: 90.75 | EPS CAGR: 8.35% | SUE: 1.06 | # QB: 3
Revenue Correlation: 61.41 | Revenue CAGR: 4.26% | SUE: 0.29 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.25 | Chg30d=+0.071 | Revisions Net=+2 | Analysts=5
EPS current Year (2026-06-30): EPS=8.86 | Chg30d=+0.227 | Revisions Net=+4 | Growth EPS=+11.1% | Growth Revenue=+14.7%
EPS next Year (2027-06-30): EPS=10.38 | Chg30d=+0.032 | Revisions Net=+4 | Growth EPS=+17.1% | Growth Revenue=+7.6%